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536Objectives: The balance between hyper- and hypocoagulable states is critical after coronary artery surgery both
with (coronary artery bypass grafting [CABG]) and without (off-pump coronary artery bypass [OPCAB]) car-
diopulmonary bypass to prevent thrombotic or bleeding complications. We aimed to quantify novel parameters
of coagulation, fibrinolysis, and overall hemostasis 6 months after CABG and OPCAB and to determine the
influences on these parameters.
Methods: A total of 63 patients (30 CABG, 33 OPCAB) had blood collected before and at various points 6
months after surgery. Fibrin and fibrinolysis time curves were generated by measuring the absorption of 405
nm each minute for 100 minutes after the addition of tissue factor and tissue plasminogen activator to cell-
free plasma. The parameters were compared with those from a group of healthy controls.
Results: The patients’ preoperative prothrombotic assay parameters were compared with those from healthy
controls. Both CABG and OPCAB patients were hypercoagulable until at least day 10 after surgery, with eleva-
tion of fibrin generation (CABG, peak day 3,þ28.9%; OPCAB, peak day 1,þ16.3% vs preoperative baseline)
and impairment of fibrinolysis capacity (CABG, day 1, 58.4%; OPCAB, day 1, 22.6%). Surgical revascu-
larization resulted in resolution of preoperative hypercoagulability by 6 months postoperatively. Patients with
preoperative myocardial infarction (MI) had prolonged hypercoagulability after surgery that was most exagger-
ated after CABG (overall hemostatic potential day 5, no MI, þ64.1% vs with MI, þ128.9% compared with
baseline; P ¼ .013).
Conclusions: Patients will be vulnerable to thrombotic events for6 weeks after coronary surgery yet will have
resolution of hypercoagulability by 6 months. Preoperative factors, such as MI, could require individualized
management of thrombosis prophylaxis in the postoperative period. (J Thorac Cardiovasc Surg 2014;148:536-43)Coronary artery bypass grafting, performed with (CABG)
and without (off-pump coronary artery bypass [OPCAB])
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The Journal of Thoracic and Cardiovascular Surgof hemostasis (ie, coagulation and fibrinolysis).1 A careful
balance between coagulation and fibrinolysis is essential,
particularly in the perioperative setting, when a prothrom-
botic state can render a patient prone to bypass graft failure,
myocardial infarction (MI), stroke, or other venous or arte-
rial thromboembolism, and a hypocoagulable state can
result in life-threatening bleeding.
Thrombin generation during CPB has traditionally been
thought to result primarily from exposure of blood to the
nonendothelialized surface of the circuit, with activation
of the intrinsic pathway of coagulation. More recently, the
primary mechanism has been shown to involve generation
of the VIIa/tissue factor (tenase) complex as a result of
the surgical injury.2,3 The activation of hemostasis during
CABG and OPCAB is complex and involves tissue factor-
mediated activation of coagulation, fibrinolysis, inflamma-
tion, and platelets.4 Coronary revascularization without the
use of CPB has been performed by some surgeons in the
hope of reducing the morbidity associated with systemic
inflammation5 and reduce the stroke risk associated with
manipulation of the ascending aorta.6ery c August 2014
Abbreviations and Acronyms
CABG ¼ coronary artery bypass grafting
CAD ¼ coronary artery disease
CPB ¼ cardiopulmonary bypass
OCP ¼ overall coagulation potential
OFP ¼ overall fibrinolytic potential
OHP ¼ overall hemostatic potential
OPCAB ¼ off-pump coronary artery bypass
PAI-1 ¼ plasminogen activator inhibitor 1
TXA ¼ tranexamic acid
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(prothrombin fragments 1þ2, thrombin–antithrombin com-
plex) andfibrinolysis (D-dimer) have suggested that bothOP-
CAB and CABG are associated with a prothrombotic state
that can persist for 1 month after surgery.7,8 Whether the
changes will be sustained beyond this time, and how the
preoperative comorbidities modulate the response to
surgery, are unknown. Preoperative MI increases the risk of
morbidity and mortality after CABG; the risk of stroke
with recent MI, in particular, is increased.9-11 MI disturbs
the normal balance of coagulation and fibrinolysis12—how-
ever, the possibility that an MI in the period immediately
before surgery influences hemostasis, and, thus, thrombotic
complications, after surgery has not been investigated.
Few clinical tests are routinely available to detect the
states of hypercoagulability. The overall hemostatic potential
(OHP) is a global assay that quantifies the ex vivo potential
for coagulation and fibrinolysis by generation of fibrin time
curves. The OHP is able to define a hypercoagulable profile
in a number of clinical prothrombotic states—pregnancy,
unprovoked venous and arterial thromboembolism, and auto-
immune conditions.13 More recently, impairment of fibrino-
lysis activity and enhancement of fibrin clot formation as
identified by the OHP assay have been associated with MI.12
In the present study, we used the OHP assay to investigate
the changes in coagulation and fibrinolysis after CABG and
OPCAB. We extended these observations from the preoper-
ative period to 6 months and identify the preoperative MI as
an independent contributor to the coagulation response to
surgery.METHODS
A total of 63 patients undergoing surgical coronary revascularization
from 2010 to 2011 were invited to participate. Patients who were receiving
therapeutic anticoagulation (with unfractionated/low-molecular-weight
heparin or warfarin) immediately before surgery were not included. All pa-
tients provided written consent, and the Sydney Local Health Network Hu-
man Research Ethics Committee approved the present study (X09-0322).
Surgical Revascularization
The anesthetic regimen was standardized. The patients were premedi-
cated with a benzodiazepine and opiate. Anesthesia was induced withThe Journal of Thoracic and Capropofol, fentanyl, and a nondepolarizing muscle relaxant and was main-
tained with a volatile agent. Antibiotics were administered before the in-
duction of anesthesia. Aspirin was routinely ceased in CABG patients 7
days before surgery and continued to surgery in OPCAB patients. Varia-
tions to this occurred on clinical grounds (eg, high-risk coronary disease,
bleeding risk). All patients were advised to cease medications, other than
aspirin, known to influence coagulation (eg, fish oil, nonsteroidal anti-
inflammatory agents) 7 days before surgery.
Cardiopulmonary Bypass
Patients undergoing CABG with CPB received systemic heparinization
(400 IU/kg) to maintain an activated clotting time of>400 seconds. At the
conclusion of CPB, heparin was reversed with protamine (1 mg/100 IU of
heparin given, then additional as required for an activated clotting time
within normal limits). CPBwas performedwithmild tomoderate hypother-
mia (30C-32C). The circuit consisted of a roller pump (Jostra
MedizintechnikAG,Hirrlingen, Germany), membrane oxygenator (Capiox
SX18; Terumo, Tokyo, Japan) and polyvinyl chloride circuit tubing (Ma-
quet, Rastatt, Germany) primed with 2500 mL isotonic compound lactate
solution (Hartmann’s solution; Baxter Healthcare, Sydney, Australia) and
10,000 U heparin. Pericardial blood was salvaged using cardiotomy suc-
tion. Patients were routinely given the antifibrinolytic agent, tranexamic
acid (TXA; 1.5 g loading dose, then 1 g/h until the conclusion of CPB).
Antegrade, cold cardioplegia solution (St Thomas’solution)was used to ar-
rest the heart in diastole. Rewarming began as the last distal anastomosis was
fashioned, and separation from CPB occurred once the grafts were complete
and the patients were normothermic (>36.5C). A combination of left and
right internal thoracic artery and saphenous vein grafts were used as conduits.
OPCAB Grafting
Systemic heparinization (200-300 IU/kg) was used to maintain an acti-
vated clotting time of>350 seconds and was reversed with protamine at the
conclusion of the case. Normothermia was maintained throughout. Patients
were administered a low to mid-dose of milrinone (0.2-0.4 mg/kg/min),
without a loading dose, for arterial graft vasodilation.Milrinonewas ceased
after 24 hours.
TXA (1 g) was given to 9 of the 33 OPCAB patients. The decision to
administer TXAwas determined by 1 clinician’s preference. Cell salvage
was used in all cases. Myocardial stabilization was achieved with a stabi-
lizing device (Medtronic Octopus; Medtronic, Minneapolis, Minn), and
Silastic shunts were used for distal vessel perfusion to enable a bloodless
field and prevent technical errors during the anastomosis.
Postoperative Anticoagulation
Deep vein thrombosis prophylaxis (heparin 5000 IU given subcutane-
ously, twice daily) was begun on the evening of the first postoperative
day and continued until discharge from the hospital. Aspirin was begun
on day 1 for all patients and continued indefinitely. The patients were dis-
charged from intensive care when satisfactory cardiovascular, respiratory,
and neurologic parameters had been met.
Blood Sampling and Storage
Blood samples were collected on the morning before surgery and 1, 3, 5,
and 10 days, 6 weeks, and 6 months after surgery. Blood was collected into
0.109 M sodium citrate BD Vacutainer tubes (Becton-Dickinson, Franklin
Lakes, NJ) from an antecubital vein using 21-guage butterfly needle or
from a 21-guage radial artery cannula, if that was in situ. The 10-day, 6-
week, and 6-month samples were collected after discharge from the hospi-
tal. For the 3- and 5-day samples, blood was collected immediately before
administration of subcutaneous heparin. On collection, the blood was kept
on ice for transport to the laboratory.
Within 1 hour of collection,whole bloodwas centrifuged for 10minutes at
2500g. The plasma supernatantwas then centrifuged for 10minutes at 2500g,
and the resultant platelet-poor plasma was stored in aliquots at 80C.rdiovascular Surgery c Volume 148, Number 2 537
TABLE 2. Postoperative outcomes
30-d Postoperative outcome CABG OPCAB P value
Mortality 0 0 NS
Stroke 1 0 NS
MI 0 0 NS
Blood loss (mL) 327  185 326  163 .9885
Patients transfused pRBCs (n) 12 9 .476
Patients transfused other products (n) 9 8 .836
Median ventilation time (h) 10 14.5 .0128*
Median ICU stay (d) 3.3 2.5 .5488
Median hospital stay (d) 6 6 .9664
CABG, Coronary artery bypass grafting; OPCAB, off-pump coronary artery bypass;
MI, myocardial infarction; pRBCs, packed red blood cells; ICU, intensive care unit.
*Statistically significant.
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We used a modification of the OHP assay described by He and col-
leagues.14,15 Duplicate fibrin time curves were generated in microtiter
plate wells from platelet-poor plasma. Absorption measurements at 405
nm were taken every minute for 100 minutes. A total of 100 minutes
was chosen to ensure completion of fibrinolysis. The overall coagulation
potential (OCP) wells contained 75 mL plasma, OHP buffer (final concen-
tration Tris 33 mmol/L, NaCl 65 mmol/L, CaCl2 16.5 mmol/L at pH 7.0;
tissue factor 0.85 pmol/L concentration). OHP curves were generated in
a similar fashion, but the buffer also contained tissue plasminogen activator
at a final concentration of 300 ng/mL.
The OHP and OCP values were calculated by summation of the absorp-
tion values under the respective fibrin time curves and expressed in arbi-
trary units. The overall fibrinolytic potential (OFP) represented the area
under the fibrinolytic portion of the curve as a proportion of the OCP
(OCP  OHP/OCP 3 100%) and was expressed as a percentage.
Statistical Analysis
The data are presented as the mean standard deviation. Normality was
tested using theD’Agostino-Pearsonomnibusnormality test.An independent
samples t test, 1-way analysis of variance with Dunnett’s post hoc test for
multiple comparisons, 2-way repeated measures analysis of variance, and
stepwise forward multivariate logistic regression analysis were used, as indi-
cated. The data were analyzed using the Statistical Package for Social Sci-
ences, version 18 (SPSS, Chicago, Ill). From the preliminary data, we
estimated a 20% increase in OCP as a result of surgery on day 1, with a co-
efficient of variationof 15%of themean, requiring approximately 10patients
in each surgical group for a power of 0.90 and a significance of P¼ .01. We
included 63 patients recruited during the 12months of recruitment to ensure a
similar patient recruitment and surgical environment during the study period.
RESULTS
The preoperative characteristics of 30 CABG and 33 OP-
CAB patients and 12 healthy controls aged>40 years are
summarized in Table 1. The in-hospital postoperative out-
comes are listed in Table 2.
Healthy Controls Versus Patients With Coronary
Artery Disease
The hypercoagulable OHP profile of patients with coro-
nary artery disease (CAD) awaiting surgical revascularizationTABLE 1. Preoperative characteristics
Characteristic CABG OPCAB
Healthy controls
aged>40 y
Patients 30 33 12
Age (y) 64.8  9.7 65.4  10.0 52  9.4
Female gender 6 (20.0) 7 (21.2) 8 (66.6)
Hypertension 26 (86.7) 32 (97.0) 1 (8.3)
Hypercholesterolemia or
statin use
26 (86.7) 29 (87.9) 3 (25)
Diabetes 11 (36.7) 12 (36.4) 2 (16.7)
Smoking history 21 (70.0) 17 (51.5)
Current smoker 7 (23.3) 5 (15.2) 1 (8.3)
Aspirin up to day of surgery 9 (30.0) 29 (87.9)
History of MI 14 (46.7) 17 (56.7) 0 (0)
MI within 21 d 13 (43.3) 12 (36.4)
Clopidogrel 6 (18.8) 8 (25.8)
Data presented as n, mean  standard deviation, or n (%). CABG, Coronary artery
bypass grafting; OPCAB, off-pump coronary artery bypass;MI, myocardial infarction.
538 The Journal of Thoracic and Cardiovascular Surgwas compared with that of healthy controls (healthy controls,
8.65 3.68 vs patients, 13.39 4.9; P¼ .0012). Fibrin gen-
eration (OCP)was elevated in the patients withCAD (healthy
controls, 70.30  11.87 vs patients, 87.01  13.85;
P ¼ .0002) and fibrinolysis potential (OFP) was impaired
(controls, 88.07%  2.98% vs patients, 84.80%  4.72%;
P ¼ .024).Changes in Hemostasis Early After Coronary Artery
Surgery
The patients who underwent either CABG or OPCAB
demonstrated a marked exaggeration of hypercoagulable
OHP parameters compared with the preoperative baseline
results until at least postoperative day 10 (Figure 1, A). In
both groups, fibrin generation was elevated on days 3, 5,
and 10 (OCP, CABG peak day 5, 108.2  10.49,
P ¼ .0001; and OPCAB peak day 3, 104.9  12.54,
P ¼ .0013; Figure 2). Fibrinolysis was impaired on postop-
erative days 1, 3, and 5 (CABG, OFP trough on day 1,
30.90%  33.4%, P < .00001; OPCAB, OFP trough,
66.48%  31.31%, P ¼ .0065; Figure 3).Changes in Hemostasis After CABG ComparedWith
OPCAB
No difference was found in fibrin generation (OCP) be-
tween the CABG and OPCAB groups at any points
(Figure 1, B). In contrast, fibrinolysis was significantly
more impaired after CABG than after OPCAB on day 1
(P ¼ .004); however, by day 3, the lower OFP after
CABG compared with that after OPCAB was no longer sta-
tistically significant (P ¼ .053; Figure 1, C). No difference
was found in OFP between the 2 groups at 5 and 10 days, 6
weeks, or 6 months postoperatively.
The OHP values were significantly greater 1 and 3 days
after CABG than after OPCAB (P ¼ .011 and P ¼ .035,
respectively; Figure 1). No significant difference was found
in the OHP values between the CABG and OPCAB groups
at the other measurement points.ery c August 2014
FIGURE 1. Coronary artery bypass grafting (CABG) versus off-pump
coronary artery bypass (OPCAB) to 6 months. A, overall hemostatic poten-
tial (OHP); B, overall coagulation potential (OCP); C, overall fibrinolytic
potential (OFP). *P< .05 relative to preoperative baseline; aP< .05,
bP<.01, and dP ¼ .053 between groups at indicated points.
FIGURE 2. Overall hemostatic potential (OHP) before and after surgical
revascularization compared with healthy controls. **P ¼ .0012 compared
with healthy controls.
FIGURE 3. Overall coagulation potential (OCP) of healthy controls
versus patients with or without preoperative myocardial infarction (MI).
*P<.05, no MI versus MI; aP<.01 compared with healthy controls.
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The hemostatic parameters of the patients at 6 weeks and
6 months after surgical revascularization were compared
with their preoperative values and those of the healthy con-
trols. The overall hemostatic potential did not differ signif-
icantly at 6 weeks; however, by 6 months, it was
significantly lower than the preoperative values (preopera-
tive OHP, 13.39  4.95 vs 6-week OHP, 10.74  5.65
[P ¼ .177] vs 6-month OHP, 6.55  2.06 [P ¼ .0074];
Figure 2). Fibrin generation was significantly decreased 6The Journal of Thoracic and Caweeks after surgery, and fibrinolysis had increased at 6
months after surgery, compared with preoperatively (preop-
erative OCP, 87.01 13.85 vs 6-month OCP, 77.71 13.66
[P ¼ .027]; preoperative OFP, 84.80%  4.72%, vs
6-month OCP, 91.39%  2.833% [P ¼ .0134]).Effect of Recent MI on Hemostasis Before Surgery
Of the 63 patients included in the present study, 25 (13 of
33 OPCAB patients and 12 of 30 CABG patients) experi-
enced an MI in the 21 days preceding surgical revasculari-
zation. Preoperative fibrin generation was greater in thoserdiovascular Surgery c Volume 148, Number 2 539
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14.39 vs 83.45 12.96; P ¼ .0417; Figure 3). Fibrinolysis
(OFP) and overall hemostasis (OHP) did not differ signifi-
cantly between those with versus without MI before
surgery.
Effect of Preoperative MI on Hemostasis
Postoperatively
The influence of MI (within 21 days of surgery) on post-
operative hemostasis is demonstrated in Figure 4. In all pa-
tients, by repeated measures during 4 points to day 5,
preoperative MI influenced overall hemostatic (OHP,
P ¼ .013) and fibrinolysis capacity, with the latter failing
to reach statistical significance (OFP, P ¼ .081). Preopera-
tive MI did not influence fibrin generation (OCP, P¼ .162).FIGURE 4. Preoperative myocardial infarction (MI) versus no preoperativeMI
pump coronary artery bypass (OPCAB), with overall hemostatic potential (OH
(OFP) measured. Repeated measures analysis of variance for MI (first 4 points
540 The Journal of Thoracic and Cardiovascular SurgThis pattern of postoperative hypercoagulability in patients
with preoperative MI was observed only in those undergo-
ing CABG (OHP, P¼ .035; OFP, P¼ .035; OCP, P¼ .346);
MI did not influence the OHP, OCP, or OFP in the OPCAB
patients. Stepwise multivariate analysis, including preoper-
ative and perioperative characteristics, confirmed that a
recent MI was an independent predictor of OHP 3 and 5
days postoperatively in the patient cohort when grouped
together (day 3, P¼ .024; day 5, P¼ .021) and in the group
that underwent CABG (day 3, P ¼ .049; day 5, P ¼ .022).
In patients who had experienced a preoperativeMI (more
hypercoagulable than those without MI), a trend was seen
for decreased postoperative blood loss that did not reach
statistical significance (no MI, 392  283 mL vs MI, 284
 153 mL; P ¼ .09).. Grouped into all patients, coronary artery bypass grafting (CABG) and off-
P), overall coagulation potential (OCP), and overall fibrinolytic potential
); P values for influence of MI shown.
ery c August 2014
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Hemostasis
Current smokers showed an exaggeration of impaired
postoperative fibrinolysis compared with non- or exsmokers
(OFP day 5: smokers, 64.02%  27.66% vs non- or ex-
smokers, 76.12%  7.89%; P ¼ .047). This resulted in a
trend of increased OHP 3 and 5 days after surgery that did
not reach statistical significance. A trend was seen for
decreased OFP and increased OHP in patients with diabetes
on days 3 and 5 after (but not before) surgery compared with
those without diabetes (OFP day 5, those without diabetes,
77.55%  8.08% vs those with diabetes, 67.06% 
20.85%, P ¼ .092; OHP day 5, 20.68%  12.95% vs
31.53%  21.95%, P ¼ .098).
The preoperative hemostatic potentials did not differ be-
tween the patients transfused blood products after surgery
and those who did not receive a transfusion. The transfused
patients were older (P ¼ .004), had a longer intensive care
unit and hospital stay (P¼ .009 and P¼ .027, respectively),
and showed a trend toward an increased ventilation time
(P ¼ .053).Role of TXA
All CABG patients were routinely given TXA intraoper-
atively, and 9 of 33 OPCAB patients received intraoperative
TXA. No difference was found in the amount of blood loss
between those who did and did not receive TXA. In the OP-
CAB group, no differencewas found inOFP (or other hemo-
static parameters) between thosewho did and did not receive
intraoperative TXA (OFP day 1, TXA, 60.26%  37.64%
vs no TXA, 68.97% 29.12%; P¼ .6), nor was any differ-
ence in blood loss found (TXA, 403  200 mL vs no TXA,
355  321 mL; P ¼ .6). This difference might not have
reached statistical significance owing to the small number
of patients who had received TXA in the OPCAB group.DISCUSSION
The present study used an assay of fibrin generation and
fibrinolysis to characterize the changes in hemostasis seen
in patients before and after coronary artery revasculariza-
tion performed with and without CPB.
We have reported several novel findings, including that the
individual mechanistic components of hemostasis (ie, fibri-
nolysis and coagulation) are altered differentially by CABG
and OPCAB. We have demonstrated that fibrinolysis is the
most important hemostatic parameter differentiating CABG
and OPCAB. We have also described how a preoperative
MI influences postoperative hemostasis differentially after
CABG and OPCAB.We found that at 6 months after surgical
revascularization, the patients no longer had a prothrombotic
OHP profile compared with that of healthy controls.
Patients after both CABG and OPCAB demonstrated hy-
percoagulable hemostasis parameters until 10 days afterThe Journal of Thoracic and Casurgery. The elevated OHP results from both an increase
in fibrin generation (OCP) and a decrease in the potential
for fibrinolysis (OFP). Patients at 1 and 3 days after
CABG had more hypercoagulable assay profiles available
than did the OPCAB patients—this resulted from differ-
ences in OFP between groups, rather than from any differ-
ence in OCP. Our group and others have previously
described evidence of elevated thrombin formation after
CABG and OPCAB. Vallely and colleagues8 and Parolari
and colleagues7 showed no difference in prothrombin frag-
ments 1 and 2 (PF1.2) between CABG and OPCAB after the
first 3 postoperative hours and 1 month postoperatively.
Our results have showed similarly elevated fibrin generation
(OCP) after both CABG and OPCAB until postoperative
day 10 and support these findings. The lack of a difference
between cardiac surgery performed with or without CPB
supports the limited influence of contact activation or the
intrinsic pathway on postoperative hemostasis. The pro-
longed increase in fibrin generation (OCP) can be explained
by increased plasma tissue factor described 1 month after
surgery.16 The plasma and cell-bound tissue factor were
increased as a result of the surgical injury and systemic
inflammation.
Measuring D-dimer and plasminogen, our group and
others have described very early activation of fibrinolysis
after CABG (after removal of the crossclamp). Fibrinolysis
will be similarly activated 24 hours after OPCAB.7,8 When
fibrin deposition is increased, an expected activation of
fibrinolysis occurs.4 However, the capacity to further in-
crease fibrinolysis, measured by OFP, could be limited
and, therefore, could contribute to the hypercoagulable
state. Impaired OFP might be a more useful indicator of
the prothrombotic state than relative changes in the prod-
ucts of fibrin degradation.
Impairment of fibrinolysis has been associated with post-
operative adverse thrombotic events.17 Moor and col-
leagues17 detected increased plasminogen activator
inhibitor 1 (PAI-1) in patients with early vein graft closure.
Impairment of the fibrinolytic potential after CABG and
OPCAB could have several causes. PAI-1, an endothelial
acute phase reactant, is increased 15-fold in the first 2 hours
after CABG.4 PAI-1 prevents the formation of plasmin and
thus impairs fibrinolysis. PAI-1 and tissue plasminogen
activator levels were elevated similarly after CABG and
OPCAB until at least postoperative day 6.18 All CABG pa-
tients, but only some OPCAB patients, received TXA,
which might have impaired fibrinolysis at day 1 (discussed
below).
Patients awaiting coronary revascularization had pro-
thrombotic OHP assay parameters compared with healthy
controls in a pattern similar to that recently described in
the Stockholm Heart Epidemiology Program.12
Our results suggest that surgical revascularization elimi-
nates the prothrombotic profile compared with healthyrdiovascular Surgery c Volume 148, Number 2 541
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the systems of inflammation and coagulation are well estab-
lished. Coronary revascularization does not remove the cor-
onary atherosclerotic burden but, rather, directs blood to
myocardial territories beyond the areas of stenosis. By
improving the myocardial blood supply, ischemia is
decreased; this might reduce inflammation and ameliorate
the preoperative prothrombotic state, resulting in hemostat-
ic function comparable to that of healthy controls.
MI before surgery influenced hemostasis in the postoper-
ative period. The OHP was increased at days 3 and 5, and a
trend was seen toward decreased postoperative blood loss
compared with those with no MI that did not reach statisti-
cal significance. The hypercoagulability was exaggerated in
patients who had undergone CABG. In these patients, a
trend was seen toward decreased OFP that did not reach sta-
tistical significance, but no difference was seen in OCP.
CABG includes a period of global myocardial ischemia
owing to application of an aortic crossclamp with (in our
institution) the use of cold blood cardioplegia for myocar-
dial protection. The biomarkers of myocardial injury taken
from coronary sinus blood have suggested that myocardial
injury can result from both myocardial ischemia and the in-
flammatory response to CPB.19,20 Those with preoperative
MI might be more susceptible to the myocardial ischemia,
reperfusion, or inflammatory response associated with
CPB. Also, the inflammation associated with myocardial
injury might delay recovery of the fibrinolysis potential.
Thrombin-activatable fibrinolysis inhibitor might influence
fibrinolysis to a greater extent in patients with preoperative
MI, because it will be elevated for at least until 7 days after
MI21 and for a similar period after OPCAB22 and CABG23
compared with the preoperative baseline values.
All CABG patients and 9 of 33 OPCAB patients received
intraoperative intravenous TXA, a synthetic lysine deriva-
tive that binds to plasminogen, preventing fibrinolysis.24
TXA is thought to reduce postoperative blood loss without
increasing the rate of postoperative thrombosis (stroke, MI,
deep vein thrombosis).25 The half-life of intravenous TXA
is 2 hours; 90% of the drug is excreted by glomerular filtra-
tion at 24 hours.26 In our study, the fibrinolysis potential was
more impaired after CABG than after OPCAB until day 3.
The short half-life, together with the absence of a significant
difference in OFP at any point between patients receiving
and not receiving TXA during OPCAB suggests that CPB
itself might more likely be responsible. However, this
conclusion was limited by the small number of patients
receiving TXA in the OPCAB group.
These results have a number of clinical implications.
First, patients with a preoperative MI might have less
impairment of fibrinolysis potential if they undergo
OPCAB, rather than CABG. Second, given the relatively
prolonged postoperative period of impaired fibrinolysis in
patients with preoperative MI, together with the decreased542 The Journal of Thoracic and Cardiovascular Surgpostoperative blood loss, the use of TXA in this group might
not be beneficial. Third, surgical revascularization caused
correction of the hypercoagulable state, which could
decrease patients’ future thrombotic risk. Larger clinical tri-
als are necessary to answer these questions.
Study Limitations
The OHP assay is performed on platelet-poor plasma and
thus excludes the influence of platelets on hemostasis.
Changes in the number and function of platelets in the early
period after CABG and OPCAB have been studied by our
group and others.8,27 Activation of platelets after OPCAB
might be increased in the early postoperative period. In
our study, both groups received aspirin from postoperative
day 1. However, evidence has shown varying degrees of
resistance to aspirin in a proportion of patients after both
CABG and OPCAB, and this will influence hemostasis.27,28
Although the preoperative variables and measured preop-
erative hemostatic parameters were similar between the 2
groups, because the study was not randomized, the potential
for selection bias could not be excluded. Similarly, the
different anticoagulation and antifibrinolytic regimens
used with CABG and OPCAB made it difficult to
completely isolate the role of CPB itself in hemostasis.
Rather, the present study compared the hemostatic parame-
ters of the procedures as a whole (not just the avoidance of
CPB).
CONCLUSIONS
Patients after both CABG and OPCAB remained in a pro-
thrombotic state until 10 days after surgery. This resulted
from both an increase in coagulation and impairment of
fibrinolysis potential. Patients had a more prothrombotic
profile on days 1 and 3 after CABG, relative to OPCAB. Pa-
tients with CAD have prothrombotic OHP assay parameters
before surgery; however, by 6 months after revasculariza-
tion, they will have a hemostatic profile comparable to
that of healthy controls. A preoperative MI influences post-
operative hemostasis and might warrant an individual
approach to management. Consideration should be given
to using OPCAB or increasing prophylactic anticoagulation
with medications that act on the plasma hemostatic systems
(eg, heparin). Additional studies are required to clarify
whether extending (and perhaps increasing) prophylactic
anticoagulation for a period beyond a patient’s discharge
will favorably affect the incidence of thrombotic complica-
tions in patients undergoing surgical revascularization.
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